Anixa Biosciences Treats Sixth Patient In Ongoing Phase 1 Clinical Trial Of Chimeric Antigen Receptor T-Cell Therapy For Ovarian Cancer
Portfolio Pulse from Benzinga Newsdesk
Anixa Biosciences has treated the sixth patient in its ongoing Phase 1 clinical trial of Chimeric Antigen Receptor T-Cell (CAR-T) therapy for ovarian cancer. This marks a significant milestone in the development of their innovative cancer treatment.
June 24, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anixa Biosciences has treated the sixth patient in its Phase 1 clinical trial of CAR-T therapy for ovarian cancer, marking a significant milestone in their treatment development.
The treatment of the sixth patient in the Phase 1 trial indicates progress in Anixa Biosciences' CAR-T therapy development, which could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100